Purchase this article with an account.
Maura Crowley, Omar Delgado, Karen Anderson, Wei Zheng, Holger Sellner, Nello Mainolfi, Muneto Mogi, Bruce D Jaffee, Sha-Mei Liao; Ocular complement activation and inhibition in rodent models of endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):482.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Polymorphisms in multiple complement pathway components have been found to associate with age related macular degeneration (AMD). We developed rodent models of systemic and ocular complement activation to identify complement inhibitors for the potential treatment of AMD.
C57Bl/6 mice (wild type, C3 or Factor B (FB) deficient) or Lewis rats received an intraperitoneal injection of lipopolysaccharide (LPS) at 2.5 or 1 mg/kg, respectively. At various time points after low molecular weight FB inhibitors were administered, plasma and eyes were collected. Complement activation was assessed by measuring the generation of complement C3 and FB breakdown products via Western blots in plasma and eye lysates. Levels of complement mRNAs were measured by TaqMan or microarray.
Intraperitoneal injection of LPS increased the levels of C3 and FB breakdown products C3d, iC3b, and Ba in both plasma and eye tissues. LPS-induced complement activation was time-dependent, peaking at 24 hours. LPS-challenged C3 and FB deficient mice exhibited diminished complement activation in blood and ocular tissues. C3 and FB mRNA levels in the eye were also increased by systemic LPS in a time dependent manner, peaking at 16-24 hours post LPS. Administration of FB inhibitors effectively inhibited LPS-induced complement activation in a dose dependent manner up to 100% inhibition.
Challenge with LPS induces a time-dependent ocular synthesis and breakdown of complement proteins C3 and Factor B in rodents. Absence of complement breakdown products in C3 and FB deficient mice in response to LPS indicates that the alternative pathway is responsible for the complement activation in this model system. Low molecular weight Factor B inhibitors potently inhibit both ocular and systemic complement activation. These inhibitors may be efficacious for treating complement-mediated diseases such as AMD.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only